Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia
نویسندگان
چکیده
منابع مشابه
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
BACKGROUND Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout. METHODS We randomly assigned 762 patients with gout and with serum urate concentrations of at least 8.0 mg per deciliter (480 micromol per liter) to receive either febuxostat (80 mg or 120 mg) or allopurinol (300 mg) once daily f...
متن کاملFebuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease
Febuxostat is a nonpurine xanthine oxidase (XO) inhibitor, which recently received marketing approval. However, information regarding the experience with this agent among advanced chronic kidney disease (CKD) patients is limited. In the current study, we investigated the effects of oral febuxostat in patients with advanced CKD with asymptomatic hyperuricemia. We demonstrated, for the first time...
متن کاملFebuxostat for the treatment of hyperuricemia in patients with gout
of disease process & therapeutic targets Hyperuricemia, as defined by a serum urate ≥6.8 mg/dl, is necessary but not sufficient to produce the clinical manifestations of gouty arthritis (gout) [1]. Hyperuricemia develops whenever there is a relative imbalance of production and excretion of urate. There are several other risk factors associated with the development of gout, mostly related to the...
متن کاملEfficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.
BACKGROUND Hyperuricemia is a putative risk factor for the progression of chronic kidney disease (CKD). We hypothesized that control of asymptomatic hyperuricemia may slow disease progression in CKD. STUDY DESIGN This was a single-center, double-blind, randomized, parallel-group, placebo-controlled study. SETTING & PARTICIPANTS Eligible participants were adults from Eastern India aged 18 to...
متن کاملTherapeutic Potency of Febuxostat for Hyperuricemia in Patients with Chronic Kidney Disease
Febuxostat is a non-purine xanthine oxidase inhibitor for which the metabolic pathway extensively differs from that for allopurinol. Since little information is available about the use of this agent in patients with chronic kidney disease (CKD), we investigated the effects of oral febuxostat for 2 months in patients with CKD, stage G3b–G5, and asymptomatic hyperuricemia. We found that the degre...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Kidney Diseases
سال: 2016
ISSN: 0272-6386
DOI: 10.1053/j.ajkd.2015.09.034